Breton Hill Capital Ltd. cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,611 shares of the company’s stock after selling 637 shares during the quarter. Breton Hill Capital Ltd.’s holdings in IDEXX Laboratories were worth $872,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. WMS Partners LLC lifted its position in IDEXX Laboratories by 0.3% in the second quarter. WMS Partners LLC now owns 1,583 shares of the company’s stock worth $256,000 after buying an additional 4 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in IDEXX Laboratories by 0.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,547 shares of the company’s stock worth $1,057,000 after buying an additional 19 shares during the last quarter. CAPROCK Group Inc. lifted its position in IDEXX Laboratories by 2.2% in the second quarter. CAPROCK Group Inc. now owns 1,830 shares of the company’s stock worth $295,000 after buying an additional 40 shares during the last quarter. Strs Ohio lifted its position in IDEXX Laboratories by 0.7% in the second quarter. Strs Ohio now owns 5,929 shares of the company’s stock worth $957,000 after buying an additional 41 shares during the last quarter. Finally, National Asset Management Inc. lifted its position in IDEXX Laboratories by 2.1% in the second quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock worth $332,000 after buying an additional 42 shares during the last quarter. Institutional investors own 87.71% of the company’s stock.
In other news, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,064,573 shares in the company, valued at $163,678,098.75. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Rebecca M. Henderson sold 2,578 shares of IDEXX Laboratories stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $152.86, for a total value of $394,073.08. Following the sale, the director now owns 17,274 shares of the company’s stock, valued at $2,640,503.64. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 188,734 shares of company stock valued at $28,954,266. Corporate insiders own 2.77% of the company’s stock.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded down $2.51 during trading hours on Friday, hitting $147.68. The stock had a trading volume of 493,135 shares, compared to its average volume of 557,359. IDEXX Laboratories, Inc. has a fifty-two week low of $107.59 and a fifty-two week high of $173.01. The company has a market capitalization of $13,099.38, a P/E ratio of 50.57, a price-to-earnings-growth ratio of 2.27 and a beta of 0.46. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95.
IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The business had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. During the same period last year, the company earned $0.62 earnings per share. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. analysts forecast that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Breton Hill Capital Ltd. Has $872,000 Position in IDEXX Laboratories, Inc. (IDXX)” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://sportsperspectives.com/2017/11/11/breton-hill-capital-ltd-has-872000-position-in-idexx-laboratories-inc-idxx.html.
A number of analysts recently issued reports on the company. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target for the company in a research report on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. Canaccord Genuity restated a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a research report on Friday, October 6th. Bank of America Corporation upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target for the company in a research report on Wednesday, August 23rd. Finally, BidaskClub downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. IDEXX Laboratories has an average rating of “Hold” and an average price target of $173.67.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.